Drug profile

The FDA adverse-event record for Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus

171 FDA reports name Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#577 of 2,679
by report volume (all drugs)
171
adverse-event reports
5.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus ranks #576 of 2679 by total reports (171) and #778 of 1130 by death-coded share (5.3%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#576
This drug, reports of 2679
#778
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus has 171 reports now versus 171 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus changes

Signature read: 171 reports place Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus in the upper third of FDA AER volume (#577 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
171
Total Reports
9
Deaths Reported
5.3%
Death-coded share of reports

Active Ingredients

Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus

Administration Routes

SubcutaneousParenteralUnknownSubconjunctivalOther

Species Affected

Dog 171

Most Affected Breeds

Retriever - Labrador 15
Chihuahua 13
Shepherd Dog - Australian 10
Maltese 8
Retriever - Golden 8
Shih Tzu 7
Bulldog - French 7
Terrier - Boston 6
Terrier - Yorkshire 5
Pug 5

Most Reported Reactions

Vomiting 54
Diarrhoea 21
Lack of efficacy (virus) - parvovirus (including feline panleukopenia) 21
Lethargy (see also Central nervous system depression in 'Neurological') 18
Other abnormal test result NOS 17
Facial swelling (see also 'Skin') 13
Anaphylaxis 9
Fever 8
Lethargy (see also Central nervous system depression in Neurological) 8
Not eating 7
Facial swelling (see also Skin) 7
Emesis (multiple) 6

Outcome Breakdown

Recovered/Normal
68 (39.8%)
Outcome Unknown
66 (38.6%)
Ongoing
28 (16.4%)
Died
5 (2.9%)
Euthanized
4 (2.3%)

Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus: low death-coded share in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

Similar death-coded share

Nearest other drugs by death-coded share (5.3% here), distinct from the volume row.

Betavet 5.3% Medicated Shampoo (Unknown) 5.3% Dexamethasone + Neomycin Sulfate + Thiabendazole 5.3% Salicylic Acid 5.3%

What to do with this drug

  • Compare Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus's report volume and death-coded share against similar drugs nationwide. See similar drugs
  • Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
  • Browse the full drug directory to compare report counts across products. All drugs

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Canine Distemper-Adenovirus Type 2-Parvovirus Vaccine, Modified Live Virus (#577 of 2,679 by report volume); death-coded 5.3%. PlainBreed drug row · report volume stamp 171 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →